Zymeron

Zymeron is pioneering a novel approach to cancer supportive care by developing drugs that protect the bone marrow from the toxic effects of chemotherapy and radiation. Its core technology is a proprietary peptide-drug conjugate (PDC) platform that enables targeted delivery of cytoprotective agents directly to hematopoietic stem and progenitor cells. The company's lead candidate, MyeloShield, targets a large market of approximately 9.8 million new cancer patients annually and is positioned to improve treatment outcomes, quality of life, and medication adherence. Zymeron also leverages its drug delivery and reformulation expertise through a D2-R2 program to repurpose existing drugs via the 505(b)(2) regulatory pathway.

Proprietary peptide-drug conjugate (PDC) platform for targeted bone marrow delivery and a drug reformulation platform for converting insoluble oral drugs to injectables (D2-R2 program).

Zymeron's primary competition in chemoprotection includes older, reactive therapies like G-CSFs (e.g., Neulasta) and thrombopoietin receptor agonists. A few companies are exploring proactive cytoprotection (e.g., BeyondSpring with plinabulin for neutropenia), but Zymeron's bone marrow-targeted PDC approach appears distinct. In hARS, it would compete with other medical countermeasure developers for government contracts.